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A B S T R A C T
PGC-1α controls, to a large extent, the capacity of cells to respond to changing nutritional requirements and
energetic demands. The key role of metabolic reprogramming in tumor development has highlighted the po-
tential role of PGC-1α in cancer. To investigate how loss of PGC-1α activity in primary cells impacts the on-
cogenic characteristics of spontaneously immortalized cells, and the mechanisms involved, we used the classic
3T3 protocol to generate spontaneously immortalized mouse embryonic fibroblasts (iMEFs) from wild-type (WT)
and PGC-1α knockout (KO) mice and analyzed their oncogenic potential in vivo and in vitro. We found that PGC-
1α KO iMEFs formed larger and more proliferative primary tumors than WT counterparts, and fostered the
formation of lung metastasis by B16 melanoma cells. These characteristics were associated with the reduced
capacity of KO iMEFs to respond to cell contact inhibition, in addition to an increased ability to form colonies in
soft agar, an enhanced migratory capacity, and a reduced growth factor dependence. The mechanistic basis of
this phenotype is likely associated with the observed higher levels of nuclear β-catenin and c-myc in KO iMEFs.
Evaluation of the metabolic adaptations of the immortalized cell lines identified a decrease in oxidative meta-
bolism and an increase in glycolytic flux in KO iMEFs, which were also more dependent on glutamine for their
survival. Furthermore, glucose oxidation and tricarboxylic acid cycle forward flux were reduced in KO iMEF,
resulting in the induction of compensatory anaplerotic pathways. Indeed, analysis of amino acid and lipid
patterns supported the efficient use of tricarboxylic acid cycle intermediates to synthesize lipids and proteins to
support elevated cell growth rates. All these characteristics have been observed in aggressive tumors and support
a tumor suppressor role for PGC-1α, restraining metabolic adaptations in cancer.
1. Introduction
Since Otto Warburg first hypothesized that the metabolic alterations
observed in cancer cells had a causative impact on tumor development,
the role of metabolism in cancer has been the focus of intense research
and lively debate. Warburg's central observation was that tumor cells
increase glucose uptake and lactate (Lac) secretion under aerobic con-
ditions [1]– a phenomenon now known as the Warburg effect, a term
now generally used to refer to the reduced oxidative phosphorylation
rates in cancer cells [2]. While it is generally agreed that this glycolytic
switch favors tumor growth by providing high levels of the biosynthetic
precursors needed for rapid proliferation [3], it remains unclear to what
extent the suppression of oxidative metabolism supports or is detri-
mental for tumor development or to what extent general conclusions
can apply. Indeed, there are many studies that support the oncogenic
role of oxidative metabolism [4]. Statements like “mitochondrial re-
spiration always work as a tumor suppressor” are no longer accepted,
nor other general conclusions on the role of tumor metabolism, so the
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possible efficacy of therapeutic approaches that target mitochondria is
being questioned. An emerging picture is that cancer cells need mi-
tochondria even if they are largely dysfunctional, at least in part, be-
cause they require the intermediary metabolites produced by these
organelles [5], and likely also because the production of reactive
oxygen species (ROS) by dysfunctional mitochondria favor, or are ne-
cessary for, cell proliferation [6]. Mitochondria also provide the me-
tabolic flexibility that allows cancer cells to revert to oxidative meta-
bolism to survive nutrient deprivation in the restrictive tumor
environment [7]. Resistance to chemotherapy agents [8] can also be
boosted by mitochondria, as cells with active oxidative metabolism
express high levels of stress resistance genes, including antioxidants
[9]. In addition, mitochondria can provide the plasticity necessary for
metastasis [10], and maintenance of the cancer stem cell reservoir [11].
All that being said, epidemiological studies stress the link between
metabolic dysfunctions, such as obesity, where oxidative metabolism is
reduced and increased risk of tumor development [12], and also
highlight the positive effect of interventions in patients that favor oxi-
dative metabolism such as diet [13] and exercise [14]. Accordingly,
oxidative metabolism seems to play an overall protective role in cancer,
although the underlying molecular mechanisms involved having been
only partly elucidated.
PGC-1α is a transcriptional coactivator and master regulator of
oxidative metabolism and plays a fundamental role in the metabolic
plasticity of mammalian cells. It is tightly regulated by environmental
cues to respond to changing energetic demands and nutritional status.
PGC-1α transcriptional program directly controls the number and ac-
tivity of the mitochondria [15], the antioxidant systems that prevent
the build-up of oxidants derived from the activity of the electron
transport chain (ETC) [9], as well as the genes involved in the meta-
bolism of lipids and glucose [16]. The central role of PGC-1α in me-
tabolism has led to the evaluation of its impact in tumor development.
As is generally the case when considering the role of mitochondria in
cancer, however, arguments can be made both in favor of a tumor
suppressor role and of a tumor-promoting role [17,18], a role that it
could play when working as a coactivator of ERRa [19]. In particular, in
breast cancer PGC-1α levels were initially found to be reduced in ag-
gressive tumor cell lines [20], however, later studies suggested that
PGC-1α was associated with lung metastasis of breast cancer cells and
to higher migratory capacity [21]. In melanoma PGC-1α antioxidant
capacity was linked to chemotherapy resistance [22]. However, PGC-1α
transcriptional axis was later shown to suppress melanoma metastasis
by the same group [22]. On one hand PGC-1α has also been proposed to
promote colon cancer growth [23] and on the other hand to be a good
prognosis factor for colon cancer [24] and PGC-1α KO mice are more
sensitive than WT to colon cancer induction [23]. In prostate cancer
PGC-1α has been shown to prevent metastasis [25], etc.
To investigate the role of PGC-1α in cancer from a comprehensive
perspective and the mechanisms involved, we analyzed the character-
istics of mouse embryonic fibroblasts (MEF) from both wild-type (WT)
and PGC-1α knock-out (KO) mice immortalized spontaneously in vitro
following the classical 3T3 protocol. This way we could follow the
history of PGC-1α deficient cells from their primary origin to their
immortalized state and possibly their transformation without forcing
changes in PGC-1α levels.
Molecular and functional analyses revealed that immortalized MEFs
(iMEFs) maintained the features characteristic to the role of PGC-1α in
metabolism and showed metabolic adaptations commonly found in
advanced tumors. Examination of the oncogenic properties of the iMEFs
indicated that KO cells were resistant to contact inhibition and migrated
faster than WT cells. The impact of these alterations was evaluated
using in vivo xenograft assays, which indicated that the loss of PGC-1α
results in larger primary tumors and enhances the capacity of tumor
cells to form lung metastatic nodules, overall supporting the notion that
PGC-1α plays primarily a tumor suppressor role in cancer development.
2. Materials and methods
Animals. Adult male NOD/SCID and C57BL/6 mice were used
(12–16 weeks old). Animal experimental protocols were approved by
the Institutional Animal Care and Use Committee of the CSIC and all
procedures conformed to the Declaration of Helsinki. All animals re-
ceived humane care according to the criteria outlined in the “Guide for
the Care and Use of Laboratory Animals” prepared by the National
Academy of Sciences and published by the National Institutes of Health
(No. 86–23 revised 1985).
Cell culture. Wild-type and PGC-1α KO MEFs were isolated and
cultured as previously described [26]. Wild type (n = 4) and PGC-1α
KO (n = 3) iMEF lines were obtained using the classical 3T3 protocol.
Briefly, MEFs were cultured in Dulbecco's modified essential medium
(DMEM) (Sigma-Aldrich) with 10% Fetal Bovine Serum (FBS) (Gibco),
2 mM glutamine (Gibco) and antibiotics (Gibco), counted every 72 h
using a hemocytometer and were re-seeded at 106 cells/dish. This
process was repeated until the cultures reached senescence. When
cultures escaped senescence and immortalized, cells were counted and
seeded again for 3 additional passages to determine post-immortaliza-
tion growth rates. Since spontaneous immortalization can lead to sig-
nificant genetic heterogeneity, the protocol was repeated for a total of
six MEF preparations per genotype, from six independent embryos,
derived from 3 different off-springs, that were passed independently,
and no clonal-isolation protocol was implemented. Three WT and three
KO immortalized cell lines (iMEF) were randomly selected for further
analysis. Each of the immortalized cell lines derived originally from a
different embrion. No specific selection procedure was implemented
other that, for all the cell lines used, all the original embrions were
simultaneously processed and the MEFs were simultaneously obtained
and passed. HEK293T cells and B16–V5 murine melanoma cells were
also cultured in DMEM with 10% FBS, 2 mM glutamine and antibiotics.
pH measurements. Cells (n = 3 per group) were seeded in 100-mm
dishes and cultured to confluency. The culture medium was then re-
plenished with fresh medium and the pH was measured 24 h later using
an HI 2211 pH/ORP Meter (Hanna Instruments).
Mitochondrial energetics measurements. A total of 6 × 104 cells
(n = 3 per group) were seeded per well in XF24 Cell Culture
Microplates (Seahorse Biosciences) and incubated at 37 °C overnight.
Simultaneously, XF24 FluxPacks (Seahorse Biosciences) were incubated
with XF Calibrant Solution (Seahorse Biosciences) overnight at 37 °C in
a CO2 incubator. The next day, the cell culture medium was changed to
non-buffered DMEM with 5 mM galactose. The microplate and the
FluxPlack were placed in an XFe24 Analyzer (Seahorse Biosciences)
where the oxygen consumption rate (OCR) was measured before and
after the sequential injections of oligomycin (6 μM final), FCCP (0.3 μM
final) and rotenone/antimycin A (0.1 μM final of each) (all from Sigma-
Aldrich). All samples were measured in triplicate.
13C Metabolic flux assay. Cells were cultured to confluency, washed
with PBS 1x and suspended in fresh medium containing one of the
following 6 different substrate combinations: glucose (Glc)
5 mM + glutamine (Gln) 2 mM, (1–13C) Glc 5 mM, (1–13C) Glc
5 mM + Gln 2 mM, (1–13C) Glc 5 mM + (U–13C5) Gln 2 mM, Glc
5 mM + (U–13C5) Gln 2 mM or Glc 2 mM + U–13C5 Gln 5 mM, re-
spectively. Samples (0.6 ml) of the culture medium were collected at
initiation and after 24 h and cell pellets were extracted at the end of the
incubation, as previously described [27] for 13C nuclear magnetic re-
sonance (NMR) and amino acids analysis. 1H and 13C NMR spectra were
obtained and analyzed as indicated below. n = 4 per group in each cell
culture medium condition.
High resolution 13C NMR spectroscopy. Proton-decoupled 13C NMR
spectra (22 °C, pH. 7.2) of incubation media and cellular extracts were
acquired at 11,7 T in a Bruker DRX-500 spectrometer, operating at
125,13 MHz for 13C, using a commercial 1H, 13C dual probe. In brief,
acquisition conditions were the following: π/3 pulses, 30 kHz sweep
width, 64K data table (1.7 s acquisition time), 6s total cycle time and
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either 3594 (incubation media), or 35944 (cell extracts) scans. The
proton de-coupler was gated only during the acquisition using a broad-
band composite pulse decoupling to minimize nuclear overhausser ef-
fects. Chemical shifts were calibrated with respect to an external ca-
pillary of dioxane (10% v/v, 67.4 ppm). Assignments were based on
literature values and on the addition of internal standards. 13C frac-
tional enrichments in relevant carbons were determined where in-
dicated by comparing the intensities of the corresponding 13C re-
sonance with that of the same resonance from a natural abundance
sample (1.1% 13C) obtained from cell pellets or media obtained from
incubations with unenriched substrates. See detailed description in the
Supplementary Information.
Metabolomic analysis of 13C labeled cell extracts. Samples were ana-
lyzed with liquid chromatography (UPLC 1290, Agilent Technologies)
coupled to a triple quadrupole mass spectrometer (ESI-QQQQ MS/MS
6420, Agilent Technologies) as described in detail in the Supplementary
Information.
Glutamine deprivation survival test. Cells (n = 3 per group) were
seeded in 6-well plates and cultured to confluency. Then, culture
medium was removed and fresh medium without Gln was added. Every
24 h on 4 consecutive days, cells were counted with a hemocytometer.
Colony formation assay. Cells were plated in 100 mm plates at low
density (2× 103 cells per plate). After 11 days, the colonies were fixed
with 4% paraformaldehyde (PFA) for 30 min, stained with crystal violet
(Sigma-Aldrich) for 30 min, and washed with distilled water. The dishes
were scanned and counted with ImageJ processing software (NIH), and
the colonies were photographed using a binocular magnifier MZ16 F
(Leica) equipped with a Nikon Digital Sight DS-L camera. 3–4 different
clones from each genotype were examined and experiments were made
in quintuplicate.
Soft-agar colony formation assay. Assays were performed in 6-well
plates with cells (n = 3 per group) embedded in 0.3% agarose in cul-
ture medium (3 × 105 cells per well) seeded on top of a layer of 0.6%
agarose. Colonies were photographed as above after 30 days.
Contact inhibition assay. Cells (n = 3 per group) were plated in 100-
mm plates and allowed to grow for two weeks with a medium change
every two days. Three-dimensional (3D) colony-like outgrowth struc-
tures were counted and photographed with a Nikon TS100 microscope
(Nikon) equipped with a Nikon Digital Sight DS-L camera.
Wound healing assay. Cells (n = 3 per group) were seeded in 6-well
plates and grown to confluency. A diagonal linear scratch was then
made across the center of the well using a sterile 1 ml micropipette tip.
The plate was washed three times with PBS and incubated with fresh
culture medium containing 5% FBS. Images were captured with a Zeiss
Cell Observer Z1 inverted microscope equipped with a Cascade 1K high
resolution camera (Photometrics). Images were analyzed with TScratch
software.
Boyden-chamber migration assay. 1.5 × 104 cells (n = 3 per group)
were plated onto 8-μm pore size polycarbonate membranes in a
Boyden-chamber (Costar) and allowed to migrate for 18 h. The cells
that had entered the membrane were then fixed with cold 70% ethanol
and stained with propidium iodide (Sigma-Aldrich) for 30 min at 37 °C
followed by incubation at room temperature for 1 h and 30 min. The
stained nuclei were imaged with a Zeiss LSM710 (Zeiss) spectral con-
focal microscope and analyzed using ZEN 2009 software (Zeiss) and
ImageJ.
Protein extraction and western blotting. Whole cell extracts were
prepared. Proteins were separated in 12% SDS-PAGE gels and trans-
ferred to Amersham Hybond PVDF membranes (GE Healthcare) by
semidry transference using the TransBlot SD cell system (Bio-Rad). The
following antibodies were used: PFKFB3 (Proteintech, 13763-1-AP), c-
myc (Santa Cruz Biotechnology, sc-764), Malic enzyme (kindly pro-
vided by Dr. Ángela M. Valverde, IIB, CSIC-UAM, Madrid) and β-actin
(A5441, Sigma). ImageJ software was used to analyze western blots.
RNA isolation and quantitative reverse transcription PCR (qRT-PCR).
Total mRNA was extracted with TRI Reagent (Sigma) and retro-
transcribed (RT) with M-MLV enzyme (Invitrogen). The resulting cDNA
was analyzed by qPCRs using a SYBR Green Master Mix (Applied
Biosystems) and an Eppendorf MasterCycler RealPlex platform. The
primer sets used are listed in the Supplementary Information section.
Retroviral and lentiviral vectors. Retroviral particles were generated
in HEK293T cells. pCL-Eco and pCX4-GFP were cotransfected using a
calcium phosphate transfection protocol. Twenty-four hours later, the
virus-containing culture medium was collected and passed through a
0.45 μm filter to remove cells in suspension, and 8 μg/ml of polybrene
was added to aid infection. Lentiviral particles were similarly generated
in HEK293T using VSVg, p8.9 and pHRSIN–CS–Luc-IRES-emGFP plas-
mids.
Viral infections. WT and PGC-1α KO iMEFs were infected with the
retroviral virus-containing culture medium for 20 h, whereas B16–V5
and iMEF cultures were infected by incubation with lentivirus-con-
taining culture media for 6 h. Infection efficacy was assessed by fol-
lowing the GFP expression using an inverted fluorescence microscope
(Axiovert 135, Zeiss). GFP- positive cells were selected using a
FACSVantage SE cell sorter (Becton Dickinson). Luciferase activity in
cell extracts was evaluated with a GloMax luminometer (Promega).
Cell proliferation assay in Matrigel. GFP-positive iMEFs (2 × 106)
from exponentially growing cell cultures were embedded in 200 μl a 2:1
(v/v) mixture of Matrigel (BD Biosciences) and DMEM, which was then
injected into the back of C57BL/6j mice (n = 6 per group). After 60
days the Matrigel plugs were extracted and fixed in 4% PFA for 24 h,
soaked in 30% sucrose (Sigma-Aldrich), embedded in Tissue-Tec OCT
Compound (Sakura) and frozen. Sections were prepared in a cryostat at
a thickness of 10 μm.
Xenograft tumor assay. A total of 1 × 107 cells were injected sub-
cutaneously into the back of NOD/SCID mice (n = 6 per group). Mice
were euthanized 15 days later, and tumor volume was calculated as 4/
3*π*width*length*height. Tumors were then dissected and fixed in 4%
PFA for histological analysis.
Experimental metastasis assay. A total of 5 × 105 each of iMEF and
B16–V5 cells were co-injected into the lateral tail vein of NOD/SCID
mice (n = 15 per group). Every week, mice were anaesthetized and
were injected retro-orbitally with 5 μg/mg of luciferase substrate
(Cayman). Lung metastasis was visualized in vivo using an IVIS lumina
imaging system (PerkinElmer). At 4 weeks post-inoculation, mice were
euthanized and lungs were dissected and fixed with Bouin's solution
(Sigma-Aldrich) for histological analysis.
Hematoxylin and eosin staining (H&E). Tissue sections were fixed in
10% buffered formalin and embedded in paraffin, and 4 μm sections
were de-waxed and hydrated. Sections were stained for 3 min with
Harris hematoxylin and for 2 min with eosin. Finally, the slides were
dehydrated and mounted using DPx Mountant (Sigma-Aldrich). Images
were acquired with a Nikon E90i microscope equipped with a DS-Fi1
camera and analyzed with ImageJ.
Immunofluorescence (IF). Fixation, staining and analysis procedures
were performed as previously described [28]. The following antibodies
were used: β-catenin (Santa Cruz Biotechnology, sc-1496), GFP (Santa
Cruz Biotechnology, sc-8334) and Ki67 (Thermo Scientific, RM-9106-
S1). Images were acquired with a Nikon E90i microscope equipped with
a DS-Q1 camera and analyzed with ImageJ.
Immunohistochemistry. Fixation and staining was performed with the
Vectastain ABC (Vector Labs) and the Peroxidase Substrate Kit DAB
(Vector Labs) following the manufacturer's instructions using an αKi67
antibody RM-9106-S1 (Thermo Scientific). Images were acquired with a
Nikon E90i (Nikon) microscope equipped with a DS-Fi1 camera and
analyzed with ImageJ.
Lipidomic analysis. Fatty acids from total lipids were transmethy-
lated according to Lepage & Roy [7]. The methylated fatty acids were
separated and quantified on a HP5890 series II gas chromatograph
equipped with a flame ionization detector (Agilent Technologies,
Spain). Individual fatty acids were identified comparing relative re-
tention times with commercial standards (Nu Chek, Elysian, MN, USA).
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Tridecanoic acid was used as an internal standard for quantification.
The average carbon chain length (ACL), the double bond index (DBI)
and the peroxidizability index (PI) were determined as previously de-
scribed [29].
Amino acid analysis. Amino acids were analyzed in the Protein
Chemistry facility at the Center for Biological Research (CSIC), Madrid,
on a Biochrom 30 amino acid analyzer. The Biochrom 30 uses classical
amino acid analysis methodology based on ion-exchange liquid chro-
matography and postcolumn continuous reaction with ninhydrin.
Statistical analysis. Data are expressed as mean ± SD. Statistical
significance was evaluated by two-tailed unpaired t-test, paired t-test or
analysis of variance as required. Values were considered statistically
significant at p < 0.05.
3. Results
3.1. PGC-1α KO iMEFs are more oncogenic than WT iMEFs
Aiming to analyze the role of PGC-1a in the process of cell im-
mortalization and tumurogenesis, we generated immortalized cell lines
derived from MEFs using the classical 3T3 protocol. Passage 0 for iMEFs
was considered when the cell plate where the MEFs immortalized be-
come confluent, following evaluation of cell proliferation rates for three
passages, the cells were frozen and subsequently, when all the required
cell lines were collected, they were simultaneously put again in culture
for further analysis.
As an initial test to compare and evaluate the survival and pro-
liferative capacity of WT and PGC-1α KO iMEFs in vivo, we infected
cells with a retrovirus constitutively expressing GFP, embedded them in
Matrigel, and then injected them subcutaneously into C57BL6 mice.
Matrigel was used to provide a suitable environment for anchorage,
growth and also to provide pro-angiogenic factors that facilitate access
to nutrients. After 60 days, the mice were sacrificed and the plugs were
removed, fixed and embedded in paraffin. We determined the total
number of cells per section by nuclear DAPI staining, and also measured
the percentage of GFP+ and Ki67+ (actively proliferating cells). We
found that the Matrigel plugs containing PGC-1α KO iMEFs had sig-
nificantly more cells per field than those containing WT iMEFs, and this
was accompanied by a significantly higher percentage of GFP+ and
Ki67+ cells (Fig. 1A).
To question whether the survival/proliferative capacity of iMEFs
could sustain tumor development, we injected them subcutaneously in
immunodeficient NOD-SCID mice and examined tumor appearance
after 60 days. Results showed that KO iMEF produced significantly
larger tumors than WT iMEFs (Fig. 1B). Histological analysis and eva-
luation of Ki67+ proliferative cells further showed a significantly
higher percentage of actively proliferating cells in the tumors produced
by KO iMEFs (Fig. 1C) and also the presence of hyper-proliferative
nodules, which were absent in WT iMEF-derived tumors (Fig. 1D).
Overall, these results suggest that KO iMEFs have higher survival and/
or proliferation capacity in vivo than WT iMEFs.
3.2. PGC-1α KO iMEFs facilitate the formation of lung metastases by
B16–V5 melanoma cells
While iMEFs do not have sufficient tumor formation capacity to
generate metastasis on their own, they have been shown to promote
lung metastasis formation by melanoma cells, possibly by providing an
optimal matrix environment [30]. We therefore tested the capacity of
WT and KO iMEFs to facilitate metastasis formation by co-inoculation
of iMEFs and B16–V5 melanoma cells, modified by lentiviral infection
to constitutively express luciferase. Cells were injected into the lateral
tail vein of NOD-SCID mice and luciferase expression in vivo was used to
monitor tumor development.
Lung nodules were already detectable 2 weeks after inoculation in
animals co-incoculated with KO iMEFS but not with WT iMEFs, where
nodules were only evident 4 weeks after inoculation (Fig. 2A). Fol-
lowing lung dissection, results showed that animals co-inoculated with
KO iMEFs had a significantly higher number of lung nodules than those
co-inoculated with WT iMEFs (Fig. 2B). Moreover, H&E histological
staining revealed that animals co-inoculated with KO iMEFs had larger
nodules than those co-inoculated with WT iMEFs (Fig. 2C), suggesting
that KO iMEFs have a higher capacity to promote metastasis formation
than WT iMEFs.
3.3. PGC-1α KO iMEFs present a transformed phenotype
To investigate the cellular basis for the higher oncogenic and pro-
metastatic potential of PGC-1α KO iMEFs, we used a panel of in vitro
assays to explore the different phenotypic characteristics typically as-
sociated with transformed cells.
We first looked for differences in proliferation rates in optimal ex-
ponential culture conditions, but we failed to find any significant dif-
ference between WT and KO iMEFs [31]. We next, we tested their ca-
pacity to induce cell cycle arrest in response to cell-contact inhibition.
To do this, confluent cell plates were maintained in culture with a
medium change every 2 days for up to 2 weeks, at which point we
evaluated the formation of 3D colony-like outgrowth structures. We
found that KO iMEFs, but not WT iMEFs, formed 3D colony-like
structures, suggesting that contact inhibition was impaired in KO iMEFs
(Fig. 3A).
To determine whether KO iMEFs had a general defect in the re-
sponse to extracellular cues, we next examined anchorage-independent
growth by evaluating colony formation in soft agar. We found that
whereas KO cells lines formed colonies, this capacity was almost absent
in WT cells lines (Fig. 3B).
As a complementary approach, we examined the ability of iMEFs to
form colonies when cells were plated at low densities, finding a non-
significant increase in the number of colonies from KO iMEFs relative to
WT iMEFs (Fig. 3C). Importantly, when colonies were visualized mi-
croscopically, we observed that KO iMEFs formed rough-edged colonies
wherease WT iMEFs formed compact colonies (Fig. 3C), a characteristic
normally associated with faster migration rates [32].
Continuing this analysis, we measured growth factor dependency by
testing cell survival under reduced serum conditions (0%, 0.5%, 2% and
5% FBS). Significant differences were found at 0.5%, 2% and 5% FBS
(Supp. Fig. 1) at 24 and 48 h with a higher percentage of surviving KO
iMEFs.
Given the above findings and our previous observations suggesting
that PGC-1α deficiency is associated with enhanced cell migration [33],
we used two different assays to asses migration of iMEFs: an in vitro
wound healing (scratch) assay that evaluates migration in response to
loss of cell contact and a Boyden-chamber assay that measures direc-
tional migration. We found that KO iMEFs migrated faster in both as-
says. In scratch assays, KO iMEFs closed the wound in 20 h compared
with 30 h for WT cells (Fig. 3D). Of note, the cell density at the wound
closure site was lower for KO cells, suggesting a more disorganized
migratory profile. To avoid the confounding effect of cell proliferation,
the cells were serum-starved o/n prior to the initiation of the essay. In
the Boyden chamber assay, the migrated distance after 18 h was eval-
uated by dividing the membrane into three Z-sections (top, middle and
bottom) and quantifying the percentage of cells in each section. At 18 h,
the percentage of WT cells in the top section was significantly higher
wherease the percentage of KO cells in the bottom section was higher,
supporting a faster migratory speed for KO iMEFs (Fig. 3E).
3.4. Nuclear β-catenin and c-myc levels are higher in PGC-1α KO cell lines
Loss of contact inhibition and enhanced cell migration and meta-
static potential typically characterize impaired integrin and cadherin
mediated cell contacts, leading to the activation and nuclear localiza-
tion of the oncogene β-catenin [34].
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β-catenin is present in adherens junctions in quiescent cells, but
accumulates in the nucleus in proliferative and tumor cells where it
regulates gene expression [35]. Nuclear translocation of β-catenin in
cancer cells results in the induction of many oncongenes [36] including
c-myc, an oncogene associated with most if not all the metabolic al-
terations found in tumors [37], and whose levels have been shown to
inversely correlate with those of PGC-1α in at least two types of cancer
cells [38,39].
Given that KO iMEFs displayed phenotypic characteristics re-
miniscent of tumor cells, we analyzed the sub-cellular distribution of β-
catenin by immunoflourescence, finding that the levels of nuclear β-
catenin were higher in KO cells than in WT cells (Fig. 4A). Moreover,
we detected higher levels of c-myc in western blots of KO iMEFs, an
observation consistent with a possible increase in β-catenin
Fig. 1. PGC-1α KO iMEFs have a greater oncogenic potential than WT iMEFs. A) Matrigel plugs with embedded WT and KO iMEFs from injected in C56BL/6j
mice. Top-left, H&E-stained sections. Top-center, immunofluorescence (IF) analysis of GFP+ cells. Top-right, IF analysis of Ki67+ cells. Bottom panels, quantitative
analysis of cell counts. B) Tumors dissected from NOD-SCID mice injected with WT and KO iMEFs. Left, full size tumors. Right, tumor volume. C) Histological analysis
of primary tumors. Top-left, H&E staining. Bottom left, IHQ Ki67 staining. Right, quantitative analysis of Ki67+ cells. D) Ki67 staining shows the presence of hyper-
proliferative nodules in KO but not in WT iMEFs tumors. Data are mean ± standard deviation. *, p < 0.05; **, p ≤ 0.01; ***, p ≤ 0.005.
I. Prieto, et al. 5HGR[%LRORJ\

transcriptional activity (Fig. 4B).
In order to test the relevance of c-myc induction in KO iMEFs, we
analyzed how the response to contact inhibition in vitro of the KO iMEFs
was modulated in the presence of a c-myc inhibitor, 10058-F4. One of
the KO cell lines did not tolerate the treatment, the other two showed a
reduction in the formation of 3D structures, suggesting a functionally
relevant role of c-myc induction (Supp. Fig. 2).
3.5. PGC-1α KO iMEFs are more glycolytic than WT's
The tumor metabolic switch that suppresses oxidative metabolism
and triggers glycolytic metabolism is driven to a large extent by c-myc.
Considering that PGC-1α is a master regulator of oxidative metabolism
and that c-myc levels were elevated in PGC-1α KO cell lines, we next
sought to evaluate the metabolic adaptations of the immortalized cell
lines.
To this end we first examined the protein expression levels of
PFKFB3, a kinase that positively controls the glycolytic flux and is
elevated in several cancers [40]. PFKFB3 was selected as a marker of
glycolysis because it is a highly regulated enzyme whose activity boost
the formation of fructose 2,6-bisphosphate (F2,6P2), which is, in turn, a
potent activator of 6-phosphofructo-1-kinase (PFK-1), the enzyme in
charge of the first committed rate-limiting step of glycolysis, which
makes of PFKFB3 a potent inducer of the glycolytic flux. Western
blotting showed that PFKFB3 levels were significantly higher in PGC-1α
KO iMEFs than in WT counterparts, pointing to a more glycolytic me-
tabolism in KO cells (Fig. 4C).
Elevated glycolytic rates generally result in increased lactate (Lac)
secretion to the media leading to media acidification. Therefore, de-
termination of culture medium pH can be used as a surrogate marker of
non-oxidative glucose catabolism. Evaluation of the pH in confluent
cultures revealed a higher acidification of the culture medium of KO
cells, suggesting an elevated production of Lac (Fig. 4E).
To directly evaluate the production of Lac from glucose (Glc), we
used stable isotope tracing. Thus, iMEFs were incubated in culture
medium containing glucose labeled with 13C in carbon 1 (1–13C) Glc.
Determination of (1–13C) Glc and (1–13C) Lac levels in the culture
media by NMR allowed the quantification of Glc consumption and Lac
production rates at equimolar rates, since 1 M of labeled glucose would
produce 1 M of labeled Lac, whereas the total Lac production from Glc
would be twice that. The amount of labeled CO2 produced by Glc oxi-
dation could be estimated from the difference between glucose con-
sumption and Lac production. As anticipated, we observed a sig-
nificantly higher production of labeled Lac in KO cell medium, while
Glc consumption was similar for both genotypes, suggesting a more
glycolytic metabolism in KO cells (Fig. 5A).
3.6. TCA cycle activity is reduced in the absence of PGC-1α
Given these results, we next evaluated the use of oxidative meta-
bolism to generate ATP (ATP-coupled oxygen consumption). Cell lines
were incubated in the presence of 5 mM galactose, and in the absence of
glucose, to force oxidative metabolism [41], and respiration was mea-
sured in the SeaHorse XFe24 analyzer. Results showed that both basal
and ATP-coupled oxygen consumption rates (OCR) were lower in KO
iMEFs (Fig. 4D and Supp. Fig. 2), but maximal respiratory capacity,
proton leakage and non-mitochondrial respiration were not sig-
nificantly different between KO and WT iMEFs, as evaluated by the
determination of the OCR with the sequential addition of oligomycin,
an inhibitor of complex V (ATP synthase) of the Electron Transport
Chain (ETC), FCCP, a membrane uncoupler, and rotenone and anti-
mycin A, inhibitors of ETC complex I (NADH+ ubiquinone oxidor-
eductase) and complex III, respectively (Supp. Fig. 2).
Continuing this analysis, we measured the catabolism of Pyr in the
Fig. 2. PGC-1α KO iMEFs can boost more the
metastatic potential of B16 melanoma cells
than WT iMEFs. A) Bioluminiscence detection of
metastatic nodules in NOD-SCID mice coin-
oculated with iMEFs and B16–V5 melanoma cells.
B) Lungs bearing metastasis. Left, representative
images of lungs. Righ, quantification of the
number of nodules. C) H&E staining of lung sec-
tions. Data are mean ± standard deviation. *,
p < 0.05; **, p ≤ 0.01; ***, p ≤ 0.005.
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TCA cycle (Supp. Fig. 3) using liquid chromatography-mass spectro-
metry (LC-MS). Specifically, we determined the levels of the labeled the
TCA intermediates, citrate (Cit), αKetoglutarate/2-oxoglutarate (αKG),
succinate, fumarate and malate (Supp. Fig. 3). We found that the re-
lative levels of labeled Cit, the first metabolite of the TCA cycle fol-
lowing the incorporation of the carbons derived from glucose as acetyl-
CoA, tended to be higher in KO iMEFs; however, this difference was nor
maintained for αKG and succinate, and was reversed for fumarate and
malate, which showed higher labeling in WT cells (Fig. 5B). Im-
portantly, we found a significant difference in the step-wise relative
decrease in the percentage of labeled Glc in KO iMEFs relative to
equivalent WT cells (Fig. 5B, right panel) possibly suggesting that Cit
progressed more slowly through the TCA cycle in KO cells than in WT
cells. This result is consistent with the previously established role of
PGC-1α in the control of succinate dehydrogenase (SDH) and fumarate
hydratase (FH) expression levels [42].
As the TCA cycle gradually deteriorates during tumor development
different anaplerotic systems became prevalent. The first one to be in-
duced is commonly malic Enzyme (ME), which catalyzes the formation
of pyruvate (Pyr) from malate [43] to compensate for the deficit in
malate dehydrogenase that forms oxalacetate (OAA) from malate in the
TCA cycle [44] and generates NADPH+, providing an important source
of reducing equivalents to maintain antioxidant systems [45].
To determine the activity of ME, we used stable isotope tracing and
NMR spectrum-analysis in cells labeled with (U–13C) glutamine (Gln)
and/or (1–13C) Glc. Since the only way to form (U–13C) Lac is via the
activity of ME, determination of the Lac Carbon 3 resonance peaks,
which double when the C2 carbon is also labeled, can be used to de-
termine whether the origin of Pyr is directly from Glc (glycolysis) or
derives from the incorporation of αKG into the TCA cycle, to form
malate, which leaves the mitochondria and is catalyzed by ME in the
cytosol to form Pyr. We found, that the amount of (U–13C) Lac was
significantly higher in PGC-1α KO iMEFs than in WT cells (Fig. 6A and
B), suggesting a higher level of ME activity. In accord with this, gene
expression analysis showed increased expression ME isoforms 1 and 3
in KO cell lines (Fig. 6C), and this finding was confirmed by western
blotting (Fig. 6D).
Another relevant anaplerotic pathway activated in tumor cells
Fig. 3. In vitro phenotypic characterization of
iMEFs. A) Representative images of overgrown
iMEF cell cultures. B) Formation of colonies in
soft-agar. Left, representative images. Right,
quantification of the number of colonies. C)
Formation of colonies grown at low cell densities.
Left, representative images of culture dishes
stained with crystal violet. Center, representative
images of single colonies. Right, representative
images of colony edges. Graph shows colony
number quantification. D) Wound-healing assay
using WT and KO iMEFs. Left panel, representative
images of the wound closure at different times, the
red lines mark the edge at time 0, yellow lines
mark the edge at the indicated time. Right panel,
graph representing the percentage of the re-
maining open area at each time point. E)
Migration in a Boyden chamber. Left, orthogonal
view of the porous membrane of a Boyden
chamber where immortalized iMEFs were allowed
to migrate. Cell nuclei were stained with propi-
dium iodide and visualized by confocal micro-
scopy. Right, quantitative evaluation of migrated
distances. The membrane span was divided into
three even sections, top, middle, and bottom and
the percentage of cells per section were quanti-
fied. Data are mean ± standard deviation. *,
p < 0.05; **, p ≤ 0.01; ***, p ≤ 0.005. (For
interpretation of the references to colour in this
figure legend, the reader is referred to the Web
version of this article.)
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involves the induction of the enzyme pyruvate carboxylase (PCx),
which makes use of pyruvate (Pyr) to synthesize OAA [46]. To de-
termine the relative contribution of PCx and Pyr Deshidrogenase (PDH)
to the catabolism of Pyr, we used stable isotope tracing of 1–13C Glc
metabolism, which differentially marks TCA metabolite carbon atoms
depending on which enzyme incorporates the labeled Pyr into the cycle.
In particular, PCx activity is responsible for the C2 13C mark whereas
PDH is responsible for the C4 13C mark on αKG. The amount of Glu
formed from αKG by the action of transaminases, can be determined by
NMR to evaluate the relative rate of PCx and PDH activity. We found
that KO iMEFs showed more PCx and less PDH activity than WT iMEFs,
although differences did not reach statistical significance (Fig. 6E). The
relevance of this result was supported by gene expression analysis of
PCx and Pyr deshydrogenase kinase 3 (PDK3), an inhibitor of PDH [47],
by qRT-PCR. Both genes were found to be significantly upregulated in
PGC-1α KO iMEFs (Fig. 6F).
3.7. PGC-1α KO cell lines are glutamine (Gln) dependent
While pyruvate is used predominantly for Lac formation by tumor
cells, the TCA cycle is actively used to provide biosynthetic precursors
needed for the synthesis of amino acids, nucleic acids and fatty acids,
which together support the elevated cell proliferations rates. This use of
the TCA cycle is boosted by the utilization of Gln that enters the TCA
Fig. 4. A-B, PGC-1α KO iMEFs show elevated
levels of nuclear β-catenin and c-myc. A) β-
catenin subcellular localization in iMEFs. Left, re-
presentative IF images of β-catenin staining in
PGC-1α WT and KO iMEFs. Right, Cellular cross
sections were used to determine the levels of β-
catenin nuclear staining. B) c-myc protein levels.
Left, WB of c-myc in WT and KO iMEF. Right,
quantification of c-myc protein levels. C-E, PGC-
1α KO iMEFs show reduced oxygen consump-
tion rates. C) PFKFB3 levels in WT and KO iMEFs.
Left, PFKFB3 Western blot. Right, quantification of
PFKFB3 protein levels. D) Oxygen consumption
rate (OCR) coupled to ATP production. E) Media
acidification by iMEF. Left, images of cell culture
dishes 24 h after change of media of confluent
cultures. Right, pH of culture media at 24 h. Data
are mean ± standard deviation. *, p < 0.05; **,
p ≤ 0.01; ***, p ≤ 0.005.
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cycle after deamination and transamination as αKG. As a consequence,
advanced tumors are characteristically Gln dependent [48].
To evaluate the Gln dependency, iMEFs were cultured in Gln-de-
prived culture medium and the remaining live cells were counted every
24 h. We found that whereas cell viability was compromised in all cases
following Gln deprivation, the percentage of live WT cells was sig-
nificantly higher at 24 and 48 h relative to KO cells, indicating a higher
Gln dependency in the latter (Fig. 7A).
In advanced tumors, Gln taken up by the amino acid transporter
ASCT2, is first deaminated by glutaminase (GLS) to form Glu, both
ASCT2 and GLS are targets of c-myc [49], and then a transaminase
reaction transfers the second amino group to form αKG, which can be
incorporated into the TCA cycle [50]. Glu can also produce aspartete
(Asp) to from OAA [51]. The maintenance of the OAA and Cit pools
seems to be the main molecular basis of Gln dependency in tumor cells.
It has been proposed that this provides TCA components for the
synthesis of biomolecules and alleviates the need for Pyr oxidation in
tumor cells with compromised ETC activity [51]. Indeed, Gln supple-
mentation increased Lac production in both WT and KO iMEFs
(Fig. 5A).
In addition to its incorporation into the TCA cycle, another im-
portant use of Gln is in the synthesis of other amino acids, in particular
Glu, Asp, and alanine (Ala) [52]. As a rule, quiescent and proliferative
cells have relatively different needs in terms not only of the amount but
also of the types of amino acids, and Gln plays a key role in the re-
storation of amino acid deficit in cancer cells [53]. Thus, we analyzed
the intracellular levels of amino acids using ion-exchange liquid chro-
matography and post-column continuous reaction with ninhydrin
(Supp. Fig. 4). We found that KO iMEFs had significantly less amount of
Gln and more Glu, Asp, and Ala, consistent with a strong use of Gln, at
least in part to boost Glu, Asp and Ala synthesis (Fig. 7B & Supp. Fig. 4).
To directly determine how Gln was used by the TCA cycle, iMEFs
were incubated with 13C Gln, (U–13C5) Gln. Were prepared cell extracts
and analyzed the incorporation of labeled Gln to Cit by LC-MS. It has
been proposed that the synthesis of Cit from αKG by reductive car-
boxylation can be induced in some aggressive tumor cell lines [54,55].
This process would directly produce Cit m+5 from Gln m+5. Analysis
showed that KO cell lines showed a higher level of 13C m+5/m+0 ratio
(Fig. 7C), possibly suggesting an active reductive carboxylation
pathway.
To evaluate this possibility we used NMR to determine the origin of
labeled acetate in cells labeled with (U–13C) Gln. Acetate is formed from
Cit by the enzyme citrate lyase. In the NMR spectrum the presence of
acetate signal doublets is indicative of the presence of 13C in con-
secutive carbons. Importantly, the presence of this signal could be ob-
served only in KO cells, suggesting the presence of an active reductive
carboxylation (Fig. 7D). However, this result is tempered by the fact
that acetate can also be formed from Gln when it is used to generate Lac
following the TCA cycle and then by the action of ME generating Lac
from malate (Supp. Fig. 3).
To further test this hypothesis, we analyzed the expression levels of
IDH1, an isocitrate deshydrogenase isoform that has been proposed to
be responsible for active reductive carboxylation in tumor cells [56].
Consistently, we found that the mRNA levels of IDH1 where sig-
nificantly higher in PGC-1α KO iMEFs than in WT iMEFs (Fig. 7E).
These results are in overall agreement with previously published
data on the use of Gln in advanced tumors which has been suggested to
be due to the use of citrate as a source of carbons for fatty acid bio-
synthesis [57,58].
3.8. PGC-1α KO cell lines have increased levels of polyunsatureated fatty
acids (PUFAs)
Tumor cells show altered fatty acid (FA) profiles that may be related
to their metabolic alterations and this impacts tumor development [59].
We thus sought to evaluate how the absence of PGC-1α impacts the
cellular fatty acid profile in iMEFs. Whereas no differences were found
in the ratio of unsaturated vs saturated FAs, we did find a higher
amount of polyunsaturated fatty acids (PUFAs) in KO cells (Table 1).
This higher level of unsaturation corresponded with a higher perox-
idizability index, a higher level of double bonds and a higher n6/n3
ratio in KO cells. Among the PUFAs detected, we noted a significant
increase in the levels of arachidonic acid (20:4n-6, AA) in KO iMEFs.
Estimation of desaturase activities based on the levels of the different
FAs suggested a higher activity of the Δ5 desaturase, which is re-
sponsible for the formation of a double bond in the acid dihomo-γ-li-
nolenic acid (20:3n-6) (DGLA) to form AA. Importantly, elevated levels
of AA and Δ5 desaturase have been found in some types of cancer and
Fig. 5. Progression of metabolites through the
TCA cycle occurs at a lower pace in PGC-1α KO
iMEFs. A) iMEFs were incubated with (1–13C) Glc
with or without Gln to determine the use of Glc to
produce Lac by NMR analysis of cell culture
media. The graph shows the moles of used Glc,
produced labeled Lac. B) MS analysis of TCA in-
termediates in cell extracts of iMEFs labeled with
(1–13C) Glc. Left, percentage of labeled 13C TCA
metabolites in WT and KO iMEFs relative to the
total amount of each metabolite in the cell extract.
Center, percentage of each labeled metabolite in
KO iMEFs relative to WT cells. Right, percentage
variation in the rate of labeled metabolite in WT vs
KO iMEFs in the sequential steps of the TCA cycle.
Data are mean ± standard deviation. *,
p < 0.05; **, p ≤ 0.01; ***, p ≤ 0.005.
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reduction of desaturase activity has been reported to increase the effi-
cacy of chemotherapy in some cases [60,61]. The basis of this effect
seems to be related to the formation of pro-inflammatory intermediates
by the enzyme COX-2 [62]. Importantly, Δ5 desaturase has also been
linked to migration and invasion, while its downregulation increases E-
cadherin levels, which could also possibly link the pathway to β-catenin
[1–81] activity [63]. In contrast, there is no evidence that links desa-
turase activity to c-myc activity although altered lipid patterns have
been identified in c-myc cancer cell models [64]. The noted increases in
AA levels in KO cells might therefore also play a role in the more ag-
gressive cancer prone phenotype of the PGC-1α KO iMEFs.
4. Discussion
Reduced oxidative metabolism and mitochondrial dysfunction are
hallmarks of cancer; however, tumor cells make use mitochondria and
oxidative metabolism to boost their oncogenic potential [65]. PGC-1α is
a master regulator of oxidative metabolism that responds to limited
nutrient availability [66]. Its activities have been demonstrated to both
facilitate and inhibit tumor progression in different contexts
[21,25,38]. Here, we aimed to test, how the loss of PGC-1α activity in a
primary cell would impact its oncogenic potential following sponta-
neous immortalization, in an attempt to directly asses whether PGC-1α
is a tumor suppressor or an oncogene.
We found that, following immortalization, the metabolic differences
between PGC-1α KO iMEFs and WT cells that are characteristic of PGC-
1α activity are maintained, including, reduced oxygen consumption,
increased glycolytic flux, and reduced TCA activity (Figs. 4–5). These
changes are associated with the induction of anaplerotic systems that
typically mark advanced tumors (Figs. 6–7). Consistently, PGC-1α KO
iMEFs formed larger and more proliferative primary tumors and fa-
cilitated the metastatic potential of B16 melanoma cells (Figs. 1–2).
These characteristics are likely associated with the greater mobility of
the KO cells and their enhanced capacity to sustain cell growth, sup-
porting the role of PGC-1α as a tumor suppressor gene (Fig. 3).
Whereas PGC-1α KO iMEFs do have a proliferative advantage WT
iMEFs in optimal cell culture conditions [31], they respond poorly to
cues that inhibit cell growth such as contact inhibition and lack of
substrate anchorage. KO iMEFs are also more resistant to cell death in
limiting growth factor conditions than WT iMEFs (Fig. 3, Supp. Fig. 1).
Fig. 6. Enhanced use of anaplerotic reactions
in KO iMEFs. A-D) Evaluation of ME activity in
iMEFs. A) NMR spectra of Lac C3 from (U–13C)
Gln and/or (1–13C) Glc labeled cells. B)
Quantitative analysis of the origin of labeled Lac
C3. C) RNA expression of ME1, ME2 and ME3 in
WT and KO iMEFs. D) ME protein levels. Top,
western blotting of ME in WT and KO iMEFs.
Bottom, quantitative analysis of ME protein levels.
E-F) Evaluation PCx activity in iMEFs. E) PDH
(oxidative) or PCx (anaplerotic) TCA entry rates
for Pyr were calculated by NMR evaluation of Glu
isotopologues following incubation with (1–13C)
Glc. F) RNA expression of PDK3 and PCx in WT
and KO iMEFs. Data are mean ± standard de-
viation. *, p < 0.05; **, p ≤ 0.01; ***,
p ≤ 0.005.
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These characteristics are more typical of fully transformed cell lines
rather than of simply immortalized cells [67]. Generally, spontaneously
immortalized MEFs do not form tumors [68] and in order to test the
oncogenic potential of a particular gene using iMEFs as a test model, the
co-expression an oncogene such as RAS is necessary [68]. By contrast,
PGC-1α KO iMEFs were able to form primary tumors when injected
subcutaneously into immunodeficient mice within highly proliferative
nodules, as identified by Ki67 staining (Fig. 1). Since the in vitro data
suggest that growth rates are comparable between WT and KO iMEFs
[31], and the contribution of the host immune response is not relevant
in the mouse model used, KO iMEFs are likely to be more oncogenic
due, at least in part, to their capacity to escape growth inhibition. Even
though the contribution of angiogenesis in this model cannot be ruled
out, the finding that KO iMEFs embedded in Matrigel (which supplies
pro-angiogenic factors), proliferate more than WT iMEFs supports the
relevance of the growth-control phenotype.
In addition, KO iMEFs also display a greater migratory phenotype
(Fig. 3), first identified in primary cells [33,69]. This characteristic
could be associated with the capacity of PGC-1α to prevent metastasis
in prostate cancer [25]. Since iMEFs could not sustain metastasis for-
mation by themselves, we tested their capacity to promote metastasis
formation through co-inoculation with the highly metastatic B16–V5
cell line. Under these conditions iMEFs have been shown to contribute
to the tumor matrix and impact on tumor progression [30].
Consistently, we found that KO iMEFs promoted the formation of lung
metastasis (Fig. 2). Expression of an oncogene in this model could have
increased the metastatic potential of the iMEFs but, our rationale was to
test PGC-1α as the sole driving force, and follow the fate of PGC-1α-
deficient cells. For the same reason, rescue of the phenotype by forced
PGC-1α expression was not tested, since the “history” of a cell that did
not have PGC-1α from the outset could not be recapitulated by forced
expression following immortalization.
Loss of PGC-1α activity in cancer cells has been linked to the down-
regulation of E-cadherin, and the activation of epithelial-mesenchymal
transition (ETM) [70,71], a process that could lead to the nuclear
translocation of β-catenin and the induction of c-myc [72,73]. Fur-
thermore, in two previous studies we noted that PGC-1α deficient en-
dothelial cells had reduced levels of VE-Cadherin in the cell membrane,
and also showed alterations in the organization of the actin cytoske-
leton. Therefore, a possible link between PGC-1α and β-catenin could
be related to the formation of the cadherin complexes [74,75]. Im-
portantly, c-myc activity in cancer cells is associated with most, if not
all, the characteristics observed for the loss of PGC-1α in iMEFs, [76].
Indeed, nuclear β-catenin and c-myc levels were higher in KO iMEFs
(Fig. 4), supporting the proposed molecular basis for this phenotype. It
has been shown that β-catenin nuclear translocation following Wnt
signaling activation results in the transcriptional induction of c-myc
[77]. Importantly, c-myc and PGC-1α expression negatively correlates
Fig. 7. KO iMEFs are dependent on Gln to
produce Cit. A) Survival rates of iMEFs in the
absence of Gln. B) Concentration of the amino
acids, Gln, Glu, Asp and Ala in WT and KO iMEFs.
Data are mean ± standard deviation. C) MS
analysis of Cit in cell extracts of iMEFs labeled
with (U–13C) Gln. The graph shows the ratio Cit m
+5/m+0. D) NMR analysis of acetate from
(U–13C) Gln labeled iMEF. E) Gene expression
analysis of IDHI in iMEF. *, p < 0.05; **,
p ≤ 0.01; ***, p ≤ 0.005.
Table 1
Fatty acid profile of PGC-1α WT and KO MEF & iMEFs. KO iMEFs show higher levels of PUFAs, in particular of AA, a precursor of pro-inflammatory mediators.
Unsaturated FAs (UFA), saturated FAs (SAT), polyunsaturated FAs (PUFA), peroxidizability index (PI), double bond index (DBI), araquidonic acid (20:4n-6, AA),
desaturase Δ5 (n-6).a, PGC-1α+/+ MEFs vs PGC-1α−/- MEFs;b, PGC-1α+/+ MEFs vs PGC-1α+/+ iMEFs;c, PGC-1α−/- MEFs vs PGC-1α−/- iMEFs;d, PGC-1α+/+ iMEFs
vs PGC-1α−/- iMEFs. *, p < 0.05; **, p ≤ 0.01; ***, p ≤ 0.005.
PGC-1α+/+ MEF PGC-1α−/- MEF PGC-1α+/+ iMEF PGC-1α−/- iMEF
UFA/SAT 1.09 ± 0.08 0.99 ± 0.06 1.10 ± 0.07 1.10 ± 0.03
PUFA (% nmol) 23.98 ± 0.18 31.10 ± 1.03a** 24.70 ± 0.77 25.75 ± 3.28c*
PI 1.05 ± 0.02 1.35 ± 0.05a* 1.06 ± 0.06 1.12 ± 0.17
DBI 127.02 ± 2.40 149.17 ± 5.07a* 125.67 ± 4.98 132.35 ± 11.35
n-6/n-3 2.69 ± 0.21 3.9 ± 0.32a** 2.75 ± 0.36 3.39 ± 0.18
20:4n-6 (% nmol) 10.79 ± 0.57 17.98 ± 0.11a*** 11.36 ± 0,62 13.47 ± 3.33c***;d***
Desaturase Δ5 (C20:4n-6/C20:3n-6) 11.79 ± 1.54 18.00 ± 1.60a** 8.51 ± 6.05 18.04 ± 7.46d***
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with c-my in pancreatic cancer stem cells [38]. However, how PGC-1α
controls the β-catenin and c-myc remains to be established.
Given that PGC-1α is a master regulator of oxidative metabolism
and that metabolic dysfunction is a hallmark of cancer, we evaluated
whether KO MEFs remained metabolically distinct from WT cells after
immortalization, and if so, how these differences could be related to
their oncogenic potential. We found that KO iMEFs showed reduced
oxygen consumption and were more glycolytic than WT cells
(Figs. 4–5). KO iMEFs also exhibited reduced TCA activity for the oxi-
dation of Pyr (Figs. 5–6).
The reduced TCA rates observed in KO iMEFs is a common feature
of advanced tumors, in which, SDH and FH activities are typically re-
duced [78] and further drainage of TCA intermediates to feed inter-
mediate metabolism has to be compensated by the activation of ana-
plerotic pathways in the cytosol [79]. In this case, cytosol/
mitochondrial shuttles that normally work to incorporate oxidized in-
termediates and export reduced intermediates work in reverse.
All of these characteristics are to be expected in cells that lack PCG-
1α and confirm that the metabolic imprint associated with PGC-1α is
not lost following immortalization. Importantly, detailed evaluation of
the metabolic derangements of KO iMEFs revealed close similarities
with alterations found in advanced, aggressive tumors, such as Gln
dependency, and induction of anaplerotic pathways that aim to com-
pensate for TCA deficiencies and feed biosynthetic flux (Figs. 6–7). All
of these alterations have been proposed as targets for the development
of novel therapies since they considerably impact on the viability of the
cancer cell but not of the normal cell [80,81]. That all of these changes
can be detected in PGC-1α KO iMEFs is strong evidence for its central
role as a tumor suppressor.
In sum, characterization of the oncogenic potential and metabolic
adaptations of spontaneously immortalized PGC-1α KO MEF suggests
that lack of PGC-1α is to a large extent a hallmark of the metabolic
changes associated with tumor progression, and strongly argue in favor
of a tumor suppressor role for PGC-1α.
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